GeneDx (NASDAQ:WGS) shares maintained their ground following a reiteration of a Hold rating and a $75.00 price target by Jefferies analysts. According to InvestingPro data, analyst targets for the ...
TD Cowen analyst Daniel Brennan maintained a Buy rating on GeneDx Holdings (WGS – Research Report) today and set a price target of $118.00. The ...
Learn more about whether Clover Health Investments, Corp. or GeneDx Holdings Corp. is a better investment based on AAII's A+ ...
GAITHERSBURG, Md., January 28, 2025--GeneDx to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 18, 2025 STAMFORD, Conn., January 17, 2025--GeneDx Holdings Corp ...
GeneDx Holdings Corp. experienced a dramatic turnaround in 2024, achieving profitability and 100x returns, driven by reduced cash burn and strategic product innovations. Key growth catalysts ...
Learn more about whether The Ensign Group, Inc. or GeneDx Holdings Corp. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.
GeneDx (WGS) Holdings eported preliminary financial results for the fourth quarter and full year of 2024. “2024 was a transformative year for GeneDx, as we achieved our profitability milestone ...
GeneDx Holdings Corp. is a patient centered health intelligence company. It engages in transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and ...
“2024 was a transformative year for GeneDx, as we achieved our profitability milestone of adjusted net income, released landmark studies, strengthened our products and expanded our team to set ...
EST GeneDx (WGS) ‘committing widespread fraud’ according to insiders, Grizzly saysMaximize Your Portfolio with Data Driven ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback